In brief: Ambri; QIC; Solbec; IDT

Sydney-based biosensor developer Ambri (ASX:ABI) has made chief financial officer Jeff Carter redundant, citing a drive to redirect resources towards its biosensor platform. Ambri's current financial controller, Phillip Camilleri, will assume the role of company secretary, and take over responsibility of all financial matters.

The Queensland Investment Corporation (QIC) has become a substantial shareholder in Melbourne's Prima Biomed (ASX:PPR), with a holding of 5.6 per cent.

Perth-based biotech Solbec Pharmaceuticals (ASX:SBP) has signed up the Adelaide-based Institute of Drug Technology (ASX:IDT) to manufacture its Coramsine compound to FDA standard for Phase II clinical trials. The compound is currently being tested as a therapeutic for cancer and psoriasis.